Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

69.96B

Market cap69.96B

Price-Earnings ratio

16.54

Price-Earnings ratio16.54

Dividend yield

0.54%

Dividend yield0.54%

Average volume

692.76K

Average volume692.76K

High today

$678.12

High today$678.12

Low today

$659.53

Low today$659.53

Open price

$662.30

Open price$662.30

Volume

650.97K

Volume650.97K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$541.00

52 Week low$541.00

Stock Snapshot

The current Regeneron(REGN) stock price is $675.00, with a market capitalization of 69.96B. The stock trades at a price-to-earnings (P/E) ratio of 16.54 and offers a dividend yield of 0.54%.

On 2026-07-28, Regeneron(REGN) stock moved within a range of $659.53 to $678.12. With shares now at $675.00, the stock is trading +2.3% above its intraday low and -0.5% below the session's peak.

Trading activity shows a volume of 650.97K, compared to an average daily volume of 692.76K.

Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $821.11 and a low of $541.00.

REGN News

Simply Wall St 1d

Telix-Regeneron Radiopharma Deal and Lawsuit Could Be A Game Changer For Regeneron Pharmaceuticals

In July 2026, Telix Pharmaceuticals announced it had entered a collaboration with Regeneron Pharmaceuticals to co-develop and commercialize next-generation radi...

Simply Wall St 6d

Regeneron Pharmaceuticals Could Be 19% Undervalued After Recent Pipeline Focus

Advertisement Event overview and why Regeneron Pharmaceuticals stock is in focus Regeneron Pharmaceuticals (REGN) is back in the spotlight after a new collabo...

TipRanks 7d

Regeneron’s POTS Study Wraps Up: What REGN7544 Could Mean for REGN Investors

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, mo...

Analyst ratings

67%

of 30 ratings

Buy

66.7%

Hold

33.3%

Sell

More REGN News

TipRanks 7d

Regeneron price target raised to $1,000 from $995 at Guggenheim

Guggenheim analyst Yatin Suneja raised the firm’s price target on Regeneron (REGN) to $1,000 from $995 and keeps a Buy rating on the shares. The firm is revisin...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.